Relation between Change in Renal Function and Cardiovascular Outcomes in Atorvastatin-Treated Patients (from the Treating to New Targets [TNT] Study)

American Journal of Cardiology

Volumn 117, Issue 8, 2016, Pages 1199-1205

  Shepherd, James ^a   Breazna, Andrei ^b   Deedwania, Prakash C ^c   LaRosa, John C ^d   Wenger, Nanette K ^e   Messig, Michael ^b   Wilson, Daniel J ^b  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b PFIZER INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; CREATININE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; FATALITY; FEMALE; GLOMERULUS FILTRATION RATE; HEART ARREST; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESUSCITATION; TREATMENT OUTCOME; BLOOD; CAUSE OF DEATH; CLINICAL TRIAL; COMPLICATION; CORONARY ARTERY DISEASE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; EPIDEMIOLOGY; FOLLOW UP; KIDNEY FUNCTION TEST; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; RENAL INSUFFICIENCY, CHRONIC; RISK FACTOR; SURVIVAL RATE; TRENDS; UNITED STATES;

ADULT; AGED; ATORVASTATIN CALCIUM; CAUSE OF DEATH; CORONARY ARTERY DISEASE; CREATININE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; SURVIVAL RATE; UNITED STATES;

EID: 84959253859     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2016.01.014     Document Type: Article

References (29)

1. E.F. Elsayed, H. Tighiouart, J. Griffith, T. Kurth, A.S. Levey, D. Salem, M.J. Sarnak, and D.E. Weiner Cardiovascular disease and subsequent kidney disease Arch Intern Med 167 2007 1130 1136
2. D.E. Rifkin, M.G. Shlipak, R. Katz, L.F. Fried, D. Siscovick, M. Chonchol, A.B. Newman, and M.J. Sarnak Rapid kidney function decline and mortality risk in older adults Arch Intern Med 168 2008 2212 2218
3. M.G. Shlipak, R. Katz, B. Kestenbaum, D. Siscovick, L. Fried, A. Newman, D. Rifkin, and M.J. Sarnak Rapid decline of kidney function increases cardiovascular risk in the elderly J Am Soc Nephrol 20 2009 2625 2630
4. K. Matsushita, E. Selvin, L.D. Bash, N. Franceschini, B.C. Astor, and J. Coresh Change in estimated GFR associates with coronary heart disease and mortality J Am Soc Nephrol 20 2009 2617 2624
5. J. Shepherd, J.J. Kastelein, V. Bittner, P. Deedwania, A. Breazna, S. Dobson, D.J. Wilson, A. Zuckerman, and N.K. Wenger Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study Clin J Am Soc Nephrol 2 2007 1131 1139
6. V.G. Athyros, D.P. Mikhailidis, A.A. Papageorgiou, A.N. Symeonidis, A.N. Pehlivanidis, V.I. Bouloukos, and M. Elisaf The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) study J Clin Pathol 57 2004 728 734
7. K. Kimura, H. Shimano, K. Yokote, M. Urashima, and T. Teramoto Effects of pitavastatin (LIVALO tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease. Sub-analysis of the LIVALO Effectiveness and Safety (LIVES) study J Atheroscler Thromb 17 2010 601 609
8. D.G. Vidt, P.M. Ridker, J.T. Monyak, M.J. Schreiber, and M.D. Cressman Longitudinal assessment of estimated glomerular filtration rate in apparently healthy adults: a post hoc analysis from the JUPITER study (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin) Clin Ther 33 2011 717 725
9. Q. Geng, J. Ren, J. Song, S. Li, and H. Chen Meta-analysis of the effect of statins on renal function Am J Cardiol 114 2014 562 570
10. J. Shepherd, J.J. Kastelein, V. Bittner, P. Deedwania, A. Breazna, S. Dobson, D.J. Wilson, A. Zuckerman, and N.K. Wenger Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study J Am Coll Cardiol 51 2008 1448 1454
11. D.D. Waters, J.R. Guyton, D.M. Herrington, M.P. McGowan, N.K. Wenger, and C. Shear Treating to New Targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am J Cardiol 93 2004 154 158
12. J.C. LaRosa, S.M. Grundy, D.D. Waters, C. Shear, P. Barter, J.C. Fruchart, A.M. Gotto, H. Greten, J.J. Kastelein, J. Shepherd, and N.K. Wenger Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
13. H. Bartels, M. Bohmer, and C. Heierli Serum creatinine determination without protein precipitation Clinica Chim Acta 37 1972 193 197
14. W. Junge, B. Wilke, A. Halabi, and G. Klein Determination of reference intervals for serum creatinine, creatinine excretion and creatinine clearance with an enzymatic and a modified Jaffé method Clinica Chim Acta 344 2004 137 148
15. A.S. Levey, J.P. Bosch, J.B. Lewis, T. Greene, N. Rogers, and D. Roth A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group Ann Intern Med 130 1999 461 470
16. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification Am J Kidney Dis 39 2002 S1 S266
17. D.E. Weiner, M. Krassilnikova, H. Tighiouart, D.N. Salem, A.S. Levey, and M.J. Sarnak CKD classification based on estimated GFR over three years and subsequent cardiac and mortality outcomes: a cohort study BMC Nephrol 10 2009 26
18. M. Tonelli, L. Moye, F.M. Sacks, T. Cole, and G.C. Curhan Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease J Am Soc Nephrol 14 2003 1605 1613
19. R. Collins, J. Armitage, S. Parish, P. Sleight, and R. Peto MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 2003 2005 2016
20. B.L. Kasiske Relationship between vascular disease and age-associated changes in the human kidney Kidney Int 31 1987 1153 1159
21. H.M. Colhoun, D.J. Betteridge, P.N. Durrington, G.A. Hitman, H.A. Neil, S.J. Livingstone, V. Charlton-Menys, D.A. DeMicco, and J.H. Fuller Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS) Am J Kidney Dis 54 2009 810 819
22. P.C. Deedwania, P.H. Stone, R.S. Fayyad, R.E. Laskey, and D.J. Wilson Improvement in renal function and reduction in serum uric acid with intensive statin therapy in older patients: a post hoc analysis of the SAGE trial Drugs Aging 32 2015 1055 1065
23. G. Coritsidis, V. Rifici, S. Gupta, J. Rie, Z.H. Shan, J. Neugarten, and D. Schlondorff Preferential binding of oxidized LDL to rat glomeruli in vivo and cultured mesangial cells in vitro Kidney Int 39 1991 858 866
24. S. Kinlay, G.G. Schwartz, A.G. Olsson, N. Rifai, S.J. Leslie, W.J. Sasiela, M. Szarek, P. Libby, and P. Ganz High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study Circulation 108 2003 1560 1566
25. R. Carnevale, P. Pignatelli, S. Di Santo, S. Bartimoccia, V. Sanguigni, L. Napoleone, G. Tanzilli, S. Basili, and F. Violi Atorvastatin inhibits oxidative stress via adiponectin-mediated NADPH oxidase down-regulation in hypercholesterolemic patients Atherosclerosis 213 2010 225 234
26. R. Haynes, D. Lewis, J. Emberson, C. Reith, L. Agodoa, A. Cass, J.C. Craig, D. de Zeeuw, B. Feldt-Rasmussen, B. Fellstrom, A. Levin, D.C. Wheeler, R. Walker, W.G. Herrington, C. Baigent, and M.J. Landray Effects of lowering LDL cholesterol on progression of kidney disease J Am Soc Nephrol 25 2014 1825 1833
27. D. de Zeeuw, D.A. Anzalone, V.A. Cain, M.D. Cressman, H.J. Heerspink, B.A. Molitoris, J.T. Monyak, H.H. Parving, G. Remuzzi, J.R. Sowers, and D.G. Vidt Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial Lancet Diabetes Endocrinol 3 2015 181 190
28. A.D. Rule, T.S. Larson, E.J. Bergstralh, J.M. Slezak, S.J. Jacobsen, and F.G. Cosio Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease Ann Intern Med 141 2004 929 937
29. A.K. Bello, B. Hemmelgarn, A. Lloyd, M.T. James, B.J. Manns, S. Klarenbach, and M. Tonelli Associations among estimated glomerular filtration rate, proteinuria, and adverse cardiovascular outcomes Clin J Am Soc Nephrol 6 2011 1418 1426